Aytu Biopharma (AYTU) Cash from Operations Growth (3y) (2015 - 2026)
Aytu Biopharma (AYTU) Cash from Operations Growth (3y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 34.90% |
| 3 | Zoetis | 32.68 Bn | 30.74 Bn | 1.62 Bn | -9.94% |
| 4 | Takeda Pharmaceutical | 27.63 Bn | 23.57 Bn | 4.39 Bn | -10.80% |
| 5 | United Therapeutics | 23.16 Bn | 21.01 Bn | 648.10 Mn | 7.32% |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.34 Bn | 18.54 Bn | 1.16 Bn | -26.33% |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | 46.81% |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | 27.85% |
| 10 | Aytu Biopharma | 22.92 Mn | -3.80 Mn | 7.60 Mn | -12.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.82% |
| Dec 31, 2025 | 51.50% |
| Sep 30, 2025 | 59.20% |
| Jun 30, 2025 | 33.79% |
| Mar 31, 2025 | 10.87% |
| Dec 31, 2024 | 32.56% |
| Sep 30, 2024 | 32.09% |
| Jun 30, 2024 | 49.99% |
| Dec 31, 2023 | 64.06% |
| Sep 30, 2023 | 70.23% |
| Jun 30, 2023 | 47.40% |
| Mar 31, 2023 | -28.89% |
| Dec 31, 2022 | 25.84% |
| Sep 30, 2022 | -44.95% |
| Jun 30, 2022 | -26.88% |
| Mar 31, 2022 | -40.16% |
| Dec 31, 2021 | -27.00% |
| Sep 30, 2021 | -11.46% |
| Jun 30, 2021 | -11.51% |
| Dec 31, 2020 | 2.13% |